Top Page
IVD Medical Holding Limited
(1931)
IVD Medical Holding Limited (1931) vs. iShares MSCI Hong Kong ETF (EWH)
IVD Medical Holding Limited Business Overview & Revenue Model
IVD Medical Holding Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.08B | 3.16B | 3.09B | 2.75B | 2.73B | 2.43B |
| Gross Profit | 706.08M | 751.17M | 671.70M | 608.14M | 566.27M | 476.17M |
| EBITDA | 401.57M | 475.96M | 397.93M | 349.66M | 286.17M | 250.04M |
| Net Income | 174.25M | 260.42M | 238.16M | 210.00M | 174.54M | 158.72M |
Balance Sheet | ||||||
| Total Assets | 6.16B | 5.52B | 4.79B | 4.31B | 4.37B | 3.91B |
| Cash, Cash Equivalents and Short-Term Investments | 427.55M | 1.86B | 1.24B | 1.04B | 841.78M | 794.74M |
| Total Debt | 1.67B | 755.97M | 344.32M | 349.92M | 427.65M | 421.80M |
| Total Liabilities | 2.63B | 1.76B | 1.40B | 1.16B | 1.37B | 1.05B |
| Stockholders Equity | 3.47B | 3.71B | 3.34B | 3.15B | 2.98B | 2.85B |
Cash Flow | ||||||
| Free Cash Flow | 99.21M | 88.69M | 251.92M | 215.39M | 137.88M | 144.87M |
| Operating Cash Flow | 136.55M | 140.29M | 292.42M | 249.67M | 163.11M | 170.49M |
| Investing Cash Flow | -2.00M | -57.80M | -77.58M | 60.54M | -27.88M | -196.00M |
| Financing Cash Flow | -18.46M | 395.13M | -19.45M | -191.29M | -66.29M | -63.24M |
IVD Medical Holding Limited Technical Analysis
IVD Medical Holding Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $60.53B | 8.24 | 8.74% | 3.70% | -2.68% | -21.45% | |
71 Outperform | $65.17B | 7.24 | 7.53% | 2.65% | 2.77% | 39.24% | |
65 Neutral | HK$7.47B | 21.29 | 6.77% | 2.74% | 29.81% | 10.40% | |
58 Neutral | HK$9.68B | 51.47 | 5.07% | 1.41% | 0.33% | -44.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$746.39M | -0.67 | -69.05% | ― | -43.86% | -217.25% |
IVD Medical Holding Limited Corporate Events
IVD Medical Holding Limited has announced an extraordinary general meeting scheduled for November 26, 2025, to consider a special resolution for changing its English name to ETHK Labs Inc. This change, pending approval from the Cayman Islands Registrar of Companies, signifies a strategic rebranding effort that could impact the company’s market positioning and stakeholder perception.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited announced significant strategic advancements, including the development of the ivd.xyz Exchange, the world’s first real-world asset exchange ecosystem for medical innovative drugs. This initiative aims to address industry challenges such as low financing efficiency and poor asset liquidity. The company is also progressing with its IVDD stablecoin program, designed to facilitate efficient cross-border transactions within its ecosystem. These moves are expected to enhance the company’s capital efficiency, accelerate drug development, and bridge the gap between medical innovation and crypto-financial markets.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced a proposed change of its English name to ‘ETHK Labs Inc.’ to better reflect its new strategic positioning and future development direction. This change is part of the company’s evolution into a global high-tech intellectual property capital operation platform, emphasizing a strategy of ‘financing-M&A-integration-exit’ to create sustainable returns for shareholders. The change will not affect shareholders’ rights or the company’s daily operations, and the company will also update its logo to align with the new name.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited announced a change in its audit committee, with Ms. Tai Yang stepping down as a member effective October 20, 2025. This change is part of a broader redesignation of directors and board committee compositions, which may impact the company’s governance and operational oversight.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced the composition of its board of directors and their respective roles and functions. This announcement outlines the structure of the board and its committees, which is crucial for stakeholders to understand the governance and strategic direction of the company.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited, a company incorporated in the Cayman Islands, has announced a significant change in its board structure. Ms. Tai Yang has been redesignated from an independent non-executive director to an executive director, effective October 20, 2025. This change also involves her stepping down from the Remuneration Committee, with Mr. Zhang Jianlei taking her place. The redesignation is part of the company’s strategic adjustments and reflects Ms. Tai’s extensive background in management and finance, which is expected to contribute positively to the company’s operations and governance.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement outlines the structure of the board’s committees, which include the Audit, Remuneration, and Nomination Committees, reflecting the company’s governance framework and potentially impacting its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has acquired a property in Irvine, California, and established a US subsidiary, ETHK BANK, to advance its initiatives in stablecoins and intellectual property securitization. This strategic move aims to enhance the company’s global business synergy and create long-term value for shareholders by developing a stablecoin public blockchain technology and innovative capital operations in North America.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has confidentially submitted a draft registration statement with the U.S. SEC for a proposed dual listing on NASDAQ, marking a strategic move in its global expansion. This dual listing is expected to enhance the company’s financing opportunities, brand influence, share liquidity, corporate governance, and strategic flexibility, thereby strengthening its position in international markets.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has entered into a strategic cooperation agreement with Transcenta Holding Limited to explore the RWA Tokenization of assets related to six innovative drug pipelines, valued at over US$1.5 billion. This collaboration signifies a significant milestone in integrating technology and finance, as it marks the formal entry of high-value innovative drug intellectual property assets into capital markets in the form of RWA. The initiative will focus on advancing these drug pipelines using cutting-edge technology platforms, potentially offering First-in-Class or Best-in-Class treatments in the oncology field.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced a corporate rebranding, unveiling a new logo to reflect its strategic shift towards a global on-chain financial ecosystem. This change signifies the company’s commitment to becoming a leader in digital industry innovation, leveraging blockchain technology to build a robust and interconnected financial infrastructure. The new logo embodies the company’s vision of open empowerment and ecological interconnectivity, marking its evolution into the ‘ETHK Ecosystem’ era.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has inaugurated the ETHK Tower in Nanjing, China, marking a significant advancement in their ‘ETHK On-Chain Financial Ecosystem Strategy.’ This development positions the company as a leader in the RWA technology domain, offering a state-of-the-art facility for R&D and ecosystem empowerment. The ETHK Tower will serve as a hub for global RWA technology research, featuring world-class laboratories, data centers, and collaborative workspaces. It aims to host over 5,000 specialists, forming a robust R&D team to drive innovation and provide comprehensive digital solutions for enterprise and institutional clients.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced a strategic cooperation with Renhe International to establish the world’s first nonprescription medicines vertical RWA exchange in the United States. This collaboration is part of IVD’s broader strategy to develop a global on-chain financial ecosystem under its ETHK brand, which includes the creation of a decentralized financial platform and a focus on digital asset transformation. The company is also proposing a name change to reflect its new positioning as a technology driver within this ecosystem. The new ‘Exchange within Exchange’ model aims to enhance global asset circulation and efficiency by creating a B2B trading ecosystem for real-world assets, thus reshaping the asset value distribution model across industries.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced the establishment of joint ventures with ETHK Group, focusing on the development of a global on-chain financial ecosystem. The joint ventures, ETHK Inc and ETHK HOLDINGS LIMITED, aim to create a secure, efficient, and decentralized financial platform while strategically integrating industry players and resources to enhance the ecosystem’s competitive edge and potential for future growth.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has proposed changing its name to ETHK Labs Inc. to better reflect its strategic shift towards digital industries and on-chain financial ecosystems. This change is part of the company’s broader strategy to position itself as a global leader in digital technology and innovation, providing comprehensive technology solutions for the ETHK on-chain financial ecosystem and its global partners.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced a delay in the dispatch of a circular related to a major acquisition involving potential cryptocurrency acquisitions worth up to HK$3 billion. The circular, which was initially expected to be sent to shareholders by 5 September 2025, will now be dispatched by 19 September 2025 due to the need for additional time to finalize certain information, including unaudited pro forma financial details.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced a proposal to refresh its General Mandate, allowing the Directors to issue new shares up to 20% of the company’s issued share capital. This move is necessary as the existing mandate has been fully utilized following a previous acquisition. The proposal requires approval from independent shareholders at an Extraordinary General Meeting (EGM), and an Independent Board Committee has been established to advise on the matter. The decision aims to provide the company with greater flexibility in managing its capital and supporting future growth initiatives.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced the composition of its board of directors and their respective roles within the company. This announcement outlines the structure of the board and its committees, which include the Audit, Remuneration, and Nomination Committees, indicating a well-defined governance framework that could enhance operational oversight and strategic decision-making.
The most recent analyst rating on (HK:1931) stock is a Buy with a HK$11.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced a significant acquisition involving the purchase of 20.31% of Gofintech Quantum Innovation Limited’s shares for approximately HK$3.14 billion. This transaction, considered a discloseable transaction under the Listing Rules, will see IVD Medical becoming a substantial shareholder in Gofintech, potentially impacting its financial statements and market positioning.
The most recent analyst rating on (HK:1931) stock is a Buy with a HK$11.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited reported a 6.2% decline in revenue and a 70% drop in profit for the first half of 2025 compared to the same period in 2024. The decrease in financial performance is attributed to reduced market demand, lower gross profit margins, increased administrative expenses, and higher selling and distribution costs due to technical service fees paid to a prospective partner.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited announced a change in its board composition with the retirement of Dr. Leung Ka Sing as an independent non-executive director, effective from September 1, 2025. Dr. Leung will also step down from his roles in the audit, remuneration, and nomination committees. The company expressed gratitude for Dr. Leung’s leadership and contributions. Concurrently, Ms. Tai Yang has been appointed as a member of the remuneration committee, also effective from September 1, 2025.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has scheduled a board meeting on August 29, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend and address other business matters, potentially impacting the company’s financial strategy and shareholder returns.
IVD Medical Holding Limited has announced a potential major acquisition involving cryptocurrencies, with plans to purchase up to HK$3 billion worth of digital assets over the next 36 months. This move is part of the company’s strategy to consolidate its ETH Reserve Vault and accelerate the development of its ivd.xyz Exchange ecosystem. The acquisition mandate requires shareholder approval and is subject to the reporting and announcement requirements under the Hong Kong Stock Exchange’s Listing Rules. The company aims to leverage the volatile cryptocurrency market by making timely acquisitions, and shareholders are advised to exercise caution given the market’s unpredictability.
IVD Medical Holding Limited has announced the establishment of a global enhanced Ethereum vault as part of its strategic upgrade. This initiative aims to integrate the Ethereum ecosystem into their operations, enhancing the efficiency of medical innovative drug research and development. By designating Ethereum as a core reserve asset, the company seeks to improve capital flow, asset turnover, and risk hedging, aligning with the global trend of institutional cryptocurrency asset allocation. This move is expected to revolutionize the capital efficiency and globalization process of the medical innovative drugs industry, creating value for ecosystem participants.
IVD Medical Holding Limited has entered into a strategic cooperation framework with HashKey Group to accelerate its global enhanced Ethereum vault strategy. This partnership will enable IVD Medical to efficiently manage its Ethereum reserves, optimize transaction costs, and explore the integration of cryptocurrency assets with real economy assets, particularly in the realm of innovative drug intellectual property rights. The collaboration is expected to enhance the company’s operations by providing access to HashKey’s global market resources, technical support, and compliance ecosystem, thus driving the global development of medical innovative drugs.
IVD Medical Holding Limited has announced the completion of its first reserve purchase of Ethereum (ETH) as part of its ‘Global Enhanced ETH Vault’ strategy. The company acquired 5,190 ETH at an average price of HK$28,798.21, totaling HK$149.47 million, through HashKey Exchange. This strategic move is aimed at strengthening the company’s reserves, attracting institutional investors, and enhancing risk resilience by integrating healthcare assets with the decentralized finance ecosystem.
IVD Medical Holding Limited has announced the establishment of a global enhanced Ethereum vault as part of its strategic upgrade. This initiative aims to integrate the company’s medical innovative drug assets with the Ethereum ecosystem, enhancing capital flow and asset turnover while reducing systemic risk. The strategy involves using Ethereum as a core reserve asset, aligning with global trends in cryptocurrency asset allocation. This move is expected to improve the efficiency of medical drug research and development and facilitate a transition to a Web3 financial paradigm.